Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.

Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V.

Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019 Jan 24.


BCR-ABL affects STAT5A and STAT5B differentially.

Schaller-Schönitz M, Barzan D, Williamson AJ, Griffiths JR, Dallmann I, Battmer K, Ganser A, Whetton AD, Scherr M, Eder M.

PLoS One. 2014 May 16;9(5):e97243. doi: 10.1371/journal.pone.0097243. eCollection 2014.


Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.

Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T.

J Exp Med. 1999 Apr 19;189(8):1229-42.


Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.

Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, Rothammer K, Roussel MF, Ihle JN.

Blood. 2000 Sep 15;96(6):2277-83.


Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I.

Cancer Res. 2013 Apr 1;73(7):2052-8. doi: 10.1158/0008-5472.CAN-12-3955. Epub 2013 Feb 11.


Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B.

Smit LS, Vanderkuur JA, Stimage A, Han Y, Luo G, Yu-Lee LY, Schwartz J, Carter-Su C.

Endocrinology. 1997 Aug;138(8):3426-34.


Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A.

Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM.

J Biol Chem. 1999 Aug 6;274(32):22484-92.


Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

Cain JA, Xiang Z, O'Neal J, Kreisel F, Colson A, Luo H, Hennighausen L, Tomasson MH.

Blood. 2007 May 1;109(9):3906-14. Epub 2007 Jan 11.


STAT5 signaling is required for the efficient induction and maintenance of CML in mice.

Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr.

Blood. 2006 Jun 15;107(12):4917-25. Epub 2006 Mar 7.


Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.

Chai JH, Zhang Y, Tan WH, Chng WJ, Li B, Wang X.

BMC Cancer. 2011 Dec 9;11:512. doi: 10.1186/1471-2407-11-512.


Prolactin signalling in the mouse hypothalamus is primarily mediated by signal transducer and activator of transcription factor 5b but not 5a.

Yip SH, Eguchi R, Grattan DR, Bunn SJ.

J Neuroendocrinol. 2012 Dec;24(12):1484-91. doi: 10.1111/j.1365-2826.2012.02357.x.


Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.

Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ, Broxmeyer HE.

J Exp Med. 2000 Sep 4;192(5):719-28.


Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior.

Tang JZ, Zuo ZH, Kong XJ, Steiner M, Yin Z, Perry JK, Zhu T, Liu DX, Lobie PE.

Endocrinology. 2010 Jan;151(1):43-55. doi: 10.1210/en.2009-0651. Epub 2009 Dec 4.


Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.

Berger A, Sexl V, Valent P, Moriggl R.

Oncotarget. 2014 Oct 30;5(20):9564-76. Review.


Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.

Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, Schmitz-Van de Leur H, Müller-Newen G.

Oncogene. 2013 Aug 1;32(31):3587-97. doi: 10.1038/onc.2012.369. Epub 2012 Aug 27.


Supplemental Content

Support Center